Loading tape…Loading tape…
BDX
BDX
BDX
Becton Dickinson & Co was featured in media coverage spotlighting historically stable dividend raisers in medical devices that offer solid yields and fortress-like growth. The company holds a market capitalization of approximately $50.90 billion and generated full-year revenue of $21.84 billion. Its current profile includes a trailing twelve months EPS of 3.42, a P/E ratio of 55.64, and a free cash flow yield of 5.12%.
Based on 247wallst.comBD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
Becton, Dickinson and Company $BDX Shares Acquired by YHB Investment Advisors Inc.
BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.